FDA Approves DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Prasco Laboratories

Prasco Laboratories has secured FDA approval for dapagliflozin and metformin hydrochloride, a generic formulation that will likely become a cost-effective alternative for the management of type 2 diabetes. This launch is positioned to compete directly with branded therapies, offering significant savings to payers and potentially reshaping market dynamics in the oral antidiabetic space.